[212Pb]Pb-DOTAM-GRPR1 is a peptidic radiopharmaceutical targeting the gastrin releasing peptide receptor (GRPr), a GPCR expressed by a range of cancers including prostate, breast, pancreatic, and cervical (Patel et al. 2006; Saidi et al. 2024). This evidence concerns the gene GRPR and cancer.